Literature DB >> 27053849

Analysis of tumor-infiltrating gamma delta T cells in rectal cancer.

Liang Rong1, Ke Li1, Rui Li1, Hui-Min Liu1, Rui Sun1, Xiao-Yan Liu1.   

Abstract

AIM: To investigate the regulatory effect of Vδ1 T cells and the antitumor activity of Vδ2 T cells in rectal cancer.
METHODS: Peripheral blood, tumor tissues and para-carcinoma tissues from 20 rectal cancer patients were collected. Naïve CD4 T cells from the peripheral blood of rectal cancer patients were purified by negative selection using a Naive CD4(+) T Cell Isolation Kit II (Miltenyi Biotec). Tumor tissues and para-carcinoma tissues were minced into small pieces and digested in a triple enzyme mixture containing collagenase type IV, hyaluronidase, and deoxyribonuclease for 2 h at room temperature. After digestion, the cells were washed twice in RPMI1640 and cultured in RPMI1640 containing 10% human serum supplemented with L-glutamine and 2-mercaptoethanol and 1000 U/mL of IL-2 for the generation of T cells. Vδ1 T cells and Vδ2 T cells from tumor tissues and para-carcinoma tissues were expanded by anti-TCR γδ antibodies. The inhibitory effects of Vδ1 T cells on naïve CD4 T cells were analyzed using the CFSE method. The cytotoxicity of Vδ2 T cells on rectal cancer lines was determined by the LDH method.
RESULTS: The percentage of Vδ1 T cells in rectal tumor tissues from rectal cancer patients was significantly increased, and positively correlated with the T stage. The percentage of Vδ2 T cells in rectal tumor tissues from rectal cancer patients was significantly decreased, and negatively correlated with the T stage. After culture for 14 d with 1 μg/mL anti-TCR γδ antibodies, the percentage of Vδ1 T cells from para-carcinoma tissues was 21.45% ± 4.64%, and the percentage of Vδ2 T cells was 38.64% ± 8.05%. After culture for 14 d, the percentage of Vδ1 T cells from rectal cancer tissues was 67.45% ± 11.75% and the percentage of Vδ2 T cells was 8.94% ± 2.85%. Tumor-infiltrating Vδ1 T cells had strong inhibitory effects, and tumor-infiltrating Vδ2 T cells showed strong cytolytic activity. The inhibitory effects of Vδ1 T cells from para-carcinoma tissues and from rectal cancer tissue were not significantly different. In addition, the cytolytic activities of Vδ2 T cells from para-carcinoma tissues and from rectal cancer tissues were not significantly different.
CONCLUSION: A percentage imbalance in Vδ1 and Vδ2 T cells in rectal cancer patients may contribute to the development of rectal cancer.

Entities:  

Keywords:  Cytotoxicity; Foxp3; Rectal cancer; T cells; Vδ1 T cells; Vδ2 T cells

Mesh:

Substances:

Year:  2016        PMID: 27053849      PMCID: PMC4814643          DOI: 10.3748/wjg.v22.i13.3573

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Long-term surveillance of locally advanced rectal cancer patients with neoadjuvant chemoradiation and aggressive surgical treatment of recurrent disease: a consecutive single-centre experience.

Authors:  Matthias Zitt; Alexander DeVries; Josef Thaler; Reinhold Kafka-Ritsch; Wolfgang Eisterer; Peter Lukas; Dietmar Öfner
Journal:  Int J Colorectal Dis       Date:  2015-08-21       Impact factor: 2.571

2.  A new effect of IL-4 on human γδ T cells: promoting regulatory Vδ1 T cells via IL-10 production and inhibiting function of Vδ2 T cells.

Authors:  Yujia Mao; Shanshan Yin; Jianmin Zhang; Yu Hu; Bo Huang; Lianxian Cui; Ning Kang; Wei He
Journal:  Cell Mol Immunol       Date:  2015-03-16       Impact factor: 11.530

3.  Lymph node involvement and tumor depth in rectal cancers: an analysis of 805 patients.

Authors:  P J Sitzler; F Seow-Choen; Y H Ho; A P Leong
Journal:  Dis Colon Rectum       Date:  1997-12       Impact factor: 4.585

4.  Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.

Authors:  Rebecca C Taylor; Ami Patel; Katherine S Panageas; Klaus J Busam; Mary S Brady
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

5.  Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway.

Authors:  Guangyong Peng; Helen Y Wang; Weiyi Peng; Yukiko Kiniwa; Kook Heon Seo; Rong-Fu Wang
Journal:  Immunity       Date:  2007-07-26       Impact factor: 31.745

Review 6.  Local excision for rectal carcinoma.

Authors:  Edward Kim; John M Hwang; Julio Garcia-Aguilar
Journal:  Clin Colorectal Cancer       Date:  2008-11       Impact factor: 4.481

7.  Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets.

Authors:  Noriko Tada; Kazushige Kawai; Nelson H Tsuno; Soichiro Ishihara; Hironori Yamaguchi; Eiji Sunami; Joji Kitayama; Koji Oba; Toshiaki Watanabe
Journal:  World J Surg Oncol       Date:  2015-02-07       Impact factor: 2.754

8.  Recruitment of γδ T lymphocytes to tumors: A new role for the pleiotropic chemokine CCL2.

Authors:  Telma Lança; Bruno Silva-Santos
Journal:  Oncoimmunology       Date:  2013-07-01       Impact factor: 8.110

9.  Immunotherapy of acute myeloid leukemia based on γδ T cells.

Authors:  Julie Gertner-Dardenne; Cyril Fauriat; Norbert Vey; Daniel Olive
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

10.  Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer.

Authors:  H E Lee; S W Chae; Y J Lee; M A Kim; H S Lee; B L Lee; W H Kim
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640

View more
  18 in total

1.  Effect of PGC-1α overexpression or silencing on mitochondrial apoptosis of goat luteinized granulosa cells.

Authors:  Guo-Min Zhang; Ming-Tian Deng; Yan-Li Zhang; Yi-Xuan Fan; Yong-Jie Wan; Hai-Tao Nie; Zi-Yu Wang; Feng Wang; Zhi-Hai Lei
Journal:  J Bioenerg Biomembr       Date:  2016-11-28       Impact factor: 2.945

Review 2.  γδ T Cells: Unexpected Regulators of Cancer Development and Progression.

Authors:  Christopher Fleming; Samantha Morrissey; Yihua Cai; Jun Yan
Journal:  Trends Cancer       Date:  2017-07-17

3.  T helper type 1 polarizing γδ T cells and Scavenger receptors contribute to the pathogenesis of Pemphigus vulgaris.

Authors:  Dayasagar Das; Vivek Anand; Sujay Khandpur; Vinod K Sharma; Alpana Sharma
Journal:  Immunology       Date:  2017-10-12       Impact factor: 7.397

Review 4.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

Review 5.  Gamma-delta (γδ) T cells: friend or foe in cancer development?

Authors:  Yijing Zhao; Chao Niu; Jiuwei Cui
Journal:  J Transl Med       Date:  2018-01-10       Impact factor: 5.531

6.  Distribution and functions of γδ T cells infiltrated in the ovarian cancer microenvironment.

Authors:  Xian Chen; Wenwen Shang; Rui Xu; Ming Wu; Xiaojie Zhang; Peijun Huang; Fang Wang; Shiyang Pan
Journal:  J Transl Med       Date:  2019-05-07       Impact factor: 5.531

7.  γδ T Cells in Peripheral Blood of Glioma Patients.

Authors:  Changbo Yue; Kai Yang; Wanqing Dong; Fengxia Hu; Shoumei Zhao; Shiqin Liu
Journal:  Med Sci Monit       Date:  2018-03-27

Review 8.  γδ T Cells: Crosstalk Between Microbiota, Chronic Inflammation, and Colorectal Cancer.

Authors:  Yunben Yang; Chunjing Xu; Dang Wu; Zhen Wang; Pin Wu; Lili Li; Jian Huang; Fuming Qiu
Journal:  Front Immunol       Date:  2018-06-26       Impact factor: 7.561

Review 9.  Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local.

Authors:  C David Pauza; Mei-Ling Liou; Tyler Lahusen; Lingzhi Xiao; Rena G Lapidus; Cristiana Cairo; Haishan Li
Journal:  Front Immunol       Date:  2018-06-08       Impact factor: 7.561

Review 10.  Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.

Authors:  Emilie Picard; Chris P Verschoor; Grace W Ma; Graham Pawelec
Journal:  Front Immunol       Date:  2020-03-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.